# Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

> **NCT05468736** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novavax** · enrollment: 3600 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05468736
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-22
- **Primary completion:** 2024-01-16
- **Final completion:** 2025-10-25
- **Target enrollment:** 3600 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468736, "Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05468736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*